These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 17906685)

  • 21. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
    Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
    Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells.
    Greco SJ; Sarkar S; Casadesus G; Zhu X; Smith MA; Ashford JW; Johnston JM; Tezapsidis N
    Neurosci Lett; 2009 May; 455(3):191-4. PubMed ID: 19429119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of glycogen synthase kinase-3beta and tau phosphorylation in neuronal Golgi disassembly.
    Elyaman W; Yardin C; Hugon J
    J Neurochem; 2002 May; 81(4):870-80. PubMed ID: 12065646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
    Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
    J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease.
    Bose A; Mouton-Liger F; Paquet C; Mazot P; Vigny M; Gray F; Hugon J
    Brain Pathol; 2011 Mar; 21(2):189-200. PubMed ID: 21029237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
    Ye Q; Xu G; Lv D; Cheng Z; Li J; Hu Y
    Bioorg Med Chem; 2009 Jul; 17(13):4302-12. PubMed ID: 19481464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease.
    Sze CI; Su M; Pugazhenthi S; Jambal P; Hsu LJ; Heath J; Schultz L; Chang NS
    J Biol Chem; 2004 Jul; 279(29):30498-506. PubMed ID: 15126504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
    Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
    Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
    Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
    J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
    Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
    Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.
    Liu F; Iqbal K; Grundke-Iqbal I; Gong CX
    FEBS Lett; 2002 Oct; 530(1-3):209-14. PubMed ID: 12387894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of GSK-3β blockade on ketamine self-administration and relapse to drug-seeking behavior in rats.
    Huang X; Huang K; Zheng W; Beveridge TJ; Yang S; Li X; Li P; Zhou W; Liu Y
    Drug Alcohol Depend; 2015 Feb; 147():257-65. PubMed ID: 25497591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of glycogen synthase kinase-3beta is sufficient for airway smooth muscle hypertrophy.
    Deng H; Dokshin GA; Lei J; Goldsmith AM; Bitar KN; Fingar DC; Hershenson MB; Bentley JK
    J Biol Chem; 2008 Apr; 283(15):10198-207. PubMed ID: 18252708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture.
    Li X; Lu F; Tian Q; Yang Y; Wang Q; Wang JZ
    J Neural Transm (Vienna); 2006 Jan; 113(1):93-102. PubMed ID: 15959856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
    Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
    FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycogen synthase kinase 3beta in the nucleus accumbens core mediates cocaine-induced behavioral sensitization.
    Xu CM; Wang J; Wu P; Zhu WL; Li QQ; Xue YX; Zhai HF; Shi J; Lu L
    J Neurochem; 2009 Dec; 111(6):1357-68. PubMed ID: 19799712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells.
    Yeste-Velasco M; Folch J; Trullàs R; Abad MA; Enguita M; Pallàs M; Camins A
    Neuropharmacology; 2007 Aug; 53(2):295-307. PubMed ID: 17612578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of integrin-linked kinase induces aberrant tau phosphorylation via sustained activation of glycogen synthase kinase 3beta in N1E-115 neuroblastoma cells.
    Ishii T; Furuoka H; Muroi Y; Nishimura M
    J Biol Chem; 2003 Jul; 278(29):26970-5. PubMed ID: 12714590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.
    Wang W; Yang Y; Ying C; Li W; Ruan H; Zhu X; You Y; Han Y; Chen R; Wang Y; Li M
    Neuropharmacology; 2007 Jun; 52(8):1678-84. PubMed ID: 17517424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.